Compare NOV & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NOV | BLCO |
|---|---|---|
| Founded | 1862 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Ophthalmic Goods |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 6.0B |
| IPO Year | 1996 | 2022 |
| Metric | NOV | BLCO |
|---|---|---|
| Price | $18.40 | $16.25 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 12 |
| Target Price | $18.00 | ★ $18.55 |
| AVG Volume (30 Days) | ★ 4.0M | 417.3K |
| Earning Date | 04-27-2026 | 04-29-2026 |
| Dividend Yield | ★ 1.97% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | ★ $8,744,000,000.00 | $5,101,000,000.00 |
| Revenue This Year | N/A | $8.61 |
| Revenue Next Year | $3.04 | $5.52 |
| P/E Ratio | $46.81 | ★ N/A |
| Revenue Growth | N/A | ★ 6.47 |
| 52 Week Low | $10.84 | $10.45 |
| 52 Week High | $20.77 | $18.92 |
| Indicator | NOV | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 43.68 | 37.30 |
| Support Level | $17.70 | $14.39 |
| Resistance Level | $19.22 | $17.44 |
| Average True Range (ATR) | 0.62 | 0.53 |
| MACD | -0.18 | -0.20 |
| Stochastic Oscillator | 19.15 | 13.09 |
NOV designs, manufactures, and sells a wide range of equipment and components supplying the oil and gas industry, including rig equipment, downhole tools, drill pipe, and well casing. NOV's customers include major integrated oil companies, national oil companies, independent oil and gas companies, and drilling contractors. Its operations are organized into two reportable segments: energy products and services and energy equipment. NOV operates on a global scale, with international markets contributing nearly two-thirds of its annual revenue.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.